iCAD seeks US OK for lung cancer detector:
This article was originally published in Clinica
Computer-aided detection (CAD) provider iCAD is seeking to sell its lung cancer detection product in the US. It has submitted to the FDA a 510(k) application for clearance to market a CAD system for helping to review CT lung scans. The technology identifies roughly-spherical objects in the lung that meet radiologist-specified size, shape and brightness criteria, enabling healthcare professionals to improve workflow by spending more time reviewing potential areas of lung cancer concern, said Nashua, New Hampshire-based iCAD. The company has already formed distribution deals for its lung cancer detection technology with TeraRecon and Viatronix. As for CT-based CAD rivals, R2 Technology last year became the first firm to gain US market clearance to use its ImageChecker system to help identify lung nodules.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.